Connect with us

Hi, what are you looking for?

Jewish Business News


Israeli company developes first of its kind blood test to diagnose lung cancer

Lung cancer is one of the most violent types of cancer, responsible for the death of 1.6 million patients each year; a first of its kind blood test, developed in Israel, succeeds in diagnosing the cancer long before it spreads in the body.

blood test medical health 20745_960_720

Israeli scientists from the Rehovot-based company Nucleix succeeded in developing a first of its kind blood test to diagnose lung cancer.

The new test is able to diagnose the disease long before it spreads in the body, thus increasing the chance of survival, as many patients usually die within a few months of the diagnosis.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

Each year, approximately 1.8 million new lung cancer patients are diagnosed, a 1.59 million of whom will die within the first year post-diagnosis. Most cases are discovered by chance, after a screening test, or due to abnormal symptoms such as prolonged cough, bloody cough, breathing difficulties or weight loss.

Diagnosis of the disease is usually done via a CT scan, but its level of accuracy is not high, and in 25 percent of the cases, the lung scan shows lesions of which only 3% are indeed cancerous.

The new test was developed by Dr. Elon Ganor, CEO of Nucleix, in collaboration with his colleagues Dr. Danny Frumkin, Dr. Adam Wasserstrom and Dr. Ofer Shapira. The test is based on the genetic characterization of cancer.

Cytosine is one of the four main bases found in DNA and it is held together by three hydrogen bonds.

A study by Prof. Haim Cedar from the Hebrew University of Jerusalem found that the three hydrogen bonds molecule serves as a kind of on/off switch that activates (or deactivates) different genes and has a decisive effect on our susceptibility to cancer and other diseases. When a certain change occurs on the same molecule, a wild division of uncontrolled cells begins, resulting in the formation of cancerous tumors.

The Israeli researchers were able to isolate the specific change on that three-bonds molecule and designed a unique blood test that identifies it. To examine the efficacy of the development, two studies were conducted, involving 170 volunteers in each study: 70 were lung cancer patients and 100 were healthy, but belonged to groups at high risk for lung cancer, such as heavy smokers.

The results showed a specificity of 94% (i.e., 94% of the healthy subjects were indeed identified as healthy), and a sensitivity of 75% (i.e., 75% of the patients were indeed identified as diseased). This is a very high level of accuracy.

The researchers predict that within two years the test will be marketed to and indicated for people over the age of 50 who are considered heavy smokers (who smoke 30-pack years—i.e., one pack per day for 30 years or 2 packs per day for 15 years), or to those exposed to heavy smokers.

“This is a significant achievement after eight years of work,” Dr. Elon Ganor told Ynet. “We developed the test here in Israel. We dreamed of making a significant contribution to humanity and saving lives, and we are convinced that this test will indeed save hundreds of thousands of people every year worldwide.”

By Ynet News

(Translated and edited by N. Elias)



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Copyright © 2021 Jewish Business News